CS269981B2 - Method of grippal vaccine production - Google Patents

Method of grippal vaccine production Download PDF

Info

Publication number: CS269981B2
Authority: CS; Czechoslovakia
Prior art keywords: influenza; derivative; antigen; vaccine; hana
Prior art date: 1985-06-06

Application number

CS864197A

Other languages

Czech (cs)

English (en)

Other versions

CS419786A2 (en

Inventor

Kuniaki Nerome

Akira Oya

Kunio Ohkuma

Atsuo Inoue

Original Assignee

Nat Inst Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-06-06

Filing date

1986-06-06

Publication date

1990-05-14

1986-06-06 Application filed by Nat Inst Health filed Critical Nat Inst Health

1989-04-14 Publication of CS419786A2 publication Critical patent/CS419786A2/cs

1990-05-14 Publication of CS269981B2 publication Critical patent/CS269981B2/cs

Links

238000000034 method Methods 0.000 title claims description 13
238000004519 manufacturing process Methods 0.000 title claims description 4
229960005486 vaccine Drugs 0.000 title abstract description 25
WVCHIGAIXREVNS-UHFFFAOYSA-N 2-hydroxy-1,4-naphthoquinone Chemical compound C1=CC=C2C(O)=CC(=O)C(=O)C2=C1 WVCHIGAIXREVNS-UHFFFAOYSA-N 0.000 claims abstract description 34
239000000427 antigen Substances 0.000 claims abstract description 26
102000036639 antigens Human genes 0.000 claims abstract description 22
108091007433 antigens Proteins 0.000 claims abstract description 22
229960003971 influenza vaccine Drugs 0.000 claims abstract description 14
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 12
206010022000 influenza Diseases 0.000 claims abstract description 12
241000712461 unidentified influenza virus Species 0.000 claims abstract description 9
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 8
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims abstract description 8
229940093541 dicetylphosphate Drugs 0.000 claims abstract description 8
229940067606 lecithin Drugs 0.000 claims abstract description 8
239000000787 lecithin Substances 0.000 claims abstract description 8
235000010445 lecithin Nutrition 0.000 claims abstract description 8
239000000203 mixture Substances 0.000 claims abstract description 8
239000004094 surface-active agent Substances 0.000 claims abstract description 8
235000012000 cholesterol Nutrition 0.000 claims abstract description 6
238000000502 dialysis Methods 0.000 claims abstract description 6
238000002156 mixing Methods 0.000 claims abstract description 4
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 12
239000000872 buffer Substances 0.000 claims description 5
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 2
239000004471 Glycine Substances 0.000 claims description 2
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
AEFLONBTGZFSGQ-VKHMYHEASA-N L-isoglutamine Chemical compound NC(=O)[C@@H](N)CCC(O)=O AEFLONBTGZFSGQ-VKHMYHEASA-N 0.000 claims description 2
229960003767 alanine Drugs 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
229940024606 amino acid Drugs 0.000 claims description 2
150000001413 amino acids Chemical class 0.000 claims description 2
125000005518 carboxamido group Chemical group 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
-1 muramyldipeptide ester Chemical class 0.000 claims description 2
230000003204 osmotic effect Effects 0.000 claims description 2
229920006395 saturated elastomer Polymers 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
239000002245 particle Substances 0.000 abstract description 20
239000012528 membrane Substances 0.000 abstract description 4
230000007928 solubilization Effects 0.000 abstract description 3
238000005063 solubilization Methods 0.000 abstract description 3
229940107161 cholesterol Drugs 0.000 abstract description 2
229940028617 conventional vaccine Drugs 0.000 abstract description 2
150000002632 lipids Chemical class 0.000 abstract description 2
230000003381 solubilizing effect Effects 0.000 abstract description 2
241000700605 Viruses Species 0.000 description 15
229930006000 Sucrose Natural products 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
235000013601 eggs Nutrition 0.000 description 4
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
GMDKAFQKGCXHQQ-UQIULFSHSA-N (4r)-4-[[(2s)-2-[[(2r)-2-[(2r,3r,4r,5r)-2-acetamido-4,5-dihydroxy-1-oxo-6-(2-tetradecylhexadecanoyloxy)hexan-3-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound CCCCCCCCCCCCCCC(CCCCCCCCCCCCCC)C(=O)OC[C@@H](O)[C@@H](O)[C@H](O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(N)=O)[C@@H](NC(C)=O)C=O GMDKAFQKGCXHQQ-UQIULFSHSA-N 0.000 description 3
108700002809 B 30-muramyl dipeptide Proteins 0.000 description 3
239000012530 fluid Substances 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000000703 high-speed centrifugation Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
AMFFPHQWQAZJHI-UHFFFAOYSA-N 2-tetradecylhexadecan-1-ol Chemical class CCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCC AMFFPHQWQAZJHI-UHFFFAOYSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
229930182478 glucoside Natural products 0.000 description 1
150000008131 glucosides Chemical class 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
230000036039 immunity Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000037797 influenza A Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
WCVHUIPWSPEOIG-UHFFFAOYSA-N n,n-dimethylheptadecan-1-amine Chemical class CCCCCCCCCCCCCCCCCN(C)C WCVHUIPWSPEOIG-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
229960001153 serine Drugs 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
229940124856 vaccine component Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Cell Biology (AREA)
Botany (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CS864197A 1985-06-06 1986-06-06 Method of grippal vaccine production CS269981B2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP60123341A JPH0688911B2 (ja)	1985-06-06	1985-06-06	インフルエンザワクチン及びその製造方法

Publications (2)

Publication Number	Publication Date
CS419786A2 CS419786A2 (en)	1989-04-14
CS269981B2 true CS269981B2 (en)	1990-05-14

Family

ID=14858166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS864197A CS269981B2 (en)	1985-06-06	1986-06-06	Method of grippal vaccine production

Country Status (12)

Country	Link
US (1)	US4826687A (de)
EP (1)	EP0205098B1 (de)
JP (1)	JPH0688911B2 (de)
KR (1)	KR940001373B1 (de)
CN (1)	CN1020407C (de)
AT (1)	ATE76756T1 (de)
AU (1)	AU585353B2 (de)
CA (1)	CA1262091A (de)
CS (1)	CS269981B2 (de)
DE (1)	DE3685519T2 (de)
ES (1)	ES8707113A1 (de)
SU (1)	SU1651782A3 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5897873A (en) *	1984-04-12	1999-04-27	The Liposome Company, Inc.	Affinity associated vaccine
US6090406A (en) *	1984-04-12	2000-07-18	The Liposome Company, Inc.	Potentiation of immune responses with liposomal adjuvants
US5916588A (en) *	1984-04-12	1999-06-29	The Liposome Company, Inc.	Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5026557A (en) *	1987-09-09	1991-06-25	The Liposome Company, Inc.	Adjuvant composition
WO1990001948A1 (en) *	1988-08-25	1990-03-08	The Liposome Company, Inc.	Influenza vaccine and novel adjuvants
NZ230423A (en) *	1988-08-25	1993-08-26	Liposome Co Inc	A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
US5100662A (en) *	1989-08-23	1992-03-31	The Liposome Company, Inc.	Steroidal liposomes exhibiting enhanced stability
AU7239191A (en) *	1990-01-25	1991-08-21	University Of Colorado Foundation, Inc., The	Method for preventing immune suppression in trauma patients
JP2777258B2 (ja) *	1990-03-13	1998-07-16	第一製薬株式会社	ムラミルジペプチド含有脂質膜構造体
US5091188A (en) *	1990-04-26	1992-02-25	Haynes Duncan H	Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) *	1990-04-26	1993-09-21	Haynes Duncan H	Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
GB9018690D0 (en) *	1990-08-24	1990-10-10	Wellcome Found	Vaccines
CA2054228A1 (en) *	1990-10-30	1992-05-01	Masaharu Oki	Muramyldipeptide derivatives and influenza vaccine comprising the derivatives
BR9506885A (pt) *	1994-02-24	1997-08-19	Micro Pak Inc	Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
CA2234957C (en)	1995-10-17	2006-12-19	Inge B. Henriksen	Insoluble drug delivery
US6465016B2 (en)	1996-08-22	2002-10-15	Research Triangle Pharmaceuticals	Cyclosporiine particles
US7255877B2 (en) *	1996-08-22	2007-08-14	Jagotec Ag	Fenofibrate microparticles
AU762246B2 (en) *	1998-02-11	2003-06-19	Rtp Pharma Corporation	Method and composition for treatment of inflammatory conditions
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
ES2216517T3 (es)	1998-05-29	2004-10-16	Skyepharma Canada Inc.	Composiciones de microcapsulas termoprotegidas y procedimiento para su esterilizacion terminal con vapor.
EP1105096B1 (de)	1998-08-19	2003-10-29	Skyepharma Canada Inc.	Injizierbare wässerige propofoldispersionen
IL143197A0 (en)	1998-11-20	2002-04-21	Rtp Pharma Inc	Dispersible phospholipid stabilized microparticles
DE60020382T2 (de) *	1999-09-21	2006-01-26	Skyepharma Canada Inc., Verdun	Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
NZ522239A (en)	2000-04-20	2004-03-26	Skyepharma Canada Inc	Improved water-insoluble drug particle process
AU8847101A (en)	2000-08-31	2002-03-13	Rtp Pharma Inc	Milled particles
US20020058065A1 (en) *	2000-09-20	2002-05-16	Pol-Henri Guivarc'h	Insoluble drug particle compositions with improved fasted-fed effects
US8586094B2 (en) *	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
AU2001259099B2 (en) *	2001-02-22	2005-12-22	Skyepharma Canada Inc.	Fibrate-statin combinations with reduced fed-fasted effects
US20040071734A1 (en) *	2001-02-23	2004-04-15	Nathalie Garcon	Novel vaccine
JP2004520144A (ja) *	2001-04-27	2004-07-08	グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム	新規ワクチン
EP1416986A4 (de) *	2001-06-29	2005-12-14	Becton Dickinson Co	Intradermale freisetzung von vakzinen und gentherapeutischen mitteln mit einer mikrokanüle
JP2006522022A (ja)	2003-02-14	2006-09-28	ザキュレイターズオブザユニバーシティーオブミズーリ	プロテアソーム干渉に関連する避妊法および組成物
US20050123550A1 (en) *	2003-05-12	2005-06-09	Laurent Philippe E.	Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) *	2003-05-12	2009-09-15	Becton, Dickinson And Company	Molecules enhancing dermal delivery of influenza vaccines
TWI329130B (en)	2003-06-19	2010-08-21	Bestewil Holding Bv	Functionally reconstituted viral membranes containing adjuvant
WO2005074460A2 (en) *	2003-12-05	2005-08-18	Becton Dickinson And Company	Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
US20060121055A1 (en) *	2004-12-06	2006-06-08	Becton, Dickinson And Company, Inc.	Compositions with enhanced immunogenicity
US7468187B2 (en)	2005-10-18	2008-12-23	Iowa State University Research Foundation, Inc.	Canine influenza virus and related compositions and methods of use
EP2139908A4 (de) *	2007-03-12	2011-02-16	Antigen Express Inc	Li-suppression unter beteiligung von li-rnai in der krebs-immuntherapie
EP2278997B1 (de)	2008-04-21	2016-08-10	Nanobio Corporation	Nanoemulsions-grippeimpfstoff
WO2013006797A1 (en)	2011-07-06	2013-01-10	Nanobio Corporation	Human respiratory syncytial virus vaccine
WO2013028738A1 (en)	2011-08-22	2013-02-28	Nanobio Corporation	Herpes simplex virus nanoemulsion vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4009258A (en) *	1972-09-25	1977-02-22	The Mount Sinai School Of Medicine Of The City University Of New York	Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
CH589453A5 (de) *	1974-01-14	1977-07-15	Sandoz Ag
US4117113A (en) *	1974-06-25	1978-09-26	National Research Development Corporation	Immunological preparations
US4196191A (en) *	1975-09-29	1980-04-01	Burroughs Wellcome Co.	Biological preparations
US4261975A (en) *	1979-09-19	1981-04-14	Merck & Co., Inc.	Viral liposome particle
ATE8584T1 (de) *	1980-01-16	1984-08-15	Hans Georg Prof. Dr. Weder	Verfahren und dialysiereinrichtung zur herstellung von bilayer-vesikeln und verwendung der bilayer-vesikel.
DE3173713D1 (en) *	1980-09-05	1986-03-20	Frappier Armand Inst	Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
US4327182A (en) *	1981-01-22	1982-04-27	Connaught Laboratories Incorporated	Purification of influenza sub-unit vaccine
US4565696A (en) *	1983-08-03	1986-01-21	The Regents Of The University Of California	Production of immunogens by antigen conjugation to liposomes
FR2551758B1 (fr) *	1983-08-16	1986-01-31	Anvar	Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
IL69720A (en) *	1983-09-14	1987-08-31	Univ Ramot	Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins
US4663161A (en) *	1985-04-22	1987-05-05	Mannino Raphael J	Liposome methods and compositions

1985
- 1985-06-06 JP JP60123341A patent/JPH0688911B2/ja not_active Expired - Lifetime
1986
- 1986-05-28 US US06/867,539 patent/US4826687A/en not_active Expired - Fee Related
- 1986-06-04 CA CA000510861A patent/CA1262091A/en not_active Expired
- 1986-06-05 KR KR1019860004500A patent/KR940001373B1/ko not_active Expired - Fee Related
- 1986-06-05 SU SU864027675A patent/SU1651782A3/ru active
- 1986-06-05 ES ES555748A patent/ES8707113A1/es not_active Expired
- 1986-06-05 DE DE8686107631T patent/DE3685519T2/de not_active Expired - Fee Related
- 1986-06-05 AT AT86107631T patent/ATE76756T1/de not_active IP Right Cessation
- 1986-06-05 AU AU58365/86A patent/AU585353B2/en not_active Ceased
- 1986-06-05 EP EP86107631A patent/EP0205098B1/de not_active Expired - Lifetime
- 1986-06-06 CS CS864197A patent/CS269981B2/cs unknown
- 1986-06-06 CN CN86103717A patent/CN1020407C/zh not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA1262091A (en)	1989-10-03
KR940001373B1 (ko)	1994-02-21
AU585353B2 (en)	1989-06-15
EP0205098A3 (en)	1989-03-22
JPS61282321A (ja)	1986-12-12
EP0205098B1 (de)	1992-06-03
DE3685519T2 (de)	1993-01-21
AU5836586A (en)	1986-12-18
CS419786A2 (en)	1989-04-14
KR870000075A (ko)	1987-02-16
ES555748A0 (es)	1987-07-01
EP0205098A2 (de)	1986-12-17
US4826687A (en)	1989-05-02
ATE76756T1 (de)	1992-06-15
SU1651782A3 (ru)	1991-05-23
CN1020407C (zh)	1993-05-05
JPH0688911B2 (ja)	1994-11-09
ES8707113A1 (es)	1987-07-01
CN86103717A (zh)	1987-02-11
DE3685519D1 (de)	1992-07-09

Publication	Publication Date	Title
CS269981B2 (en)	1990-05-14	Method of grippal vaccine production
JP2703528B2 (ja)	1998-01-26	免疫原性複合体を含有するワクチン
Perrin et al.	1985	Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre-and post-exposure protection studies
EP0942928B1 (de)	2004-11-17	Impfstoffzubereitung bestehend aus untereinheiten des respiratorischen synzytialvirus (rsv)
DE69534670T2 (de)	2006-08-10	Immunstimulierende zusammensetzungen,die ein minerales salz und ein weiteres adjuvant enthalten
EP0222415A2 (de)	1987-05-20	Viraler Glycoprotein-Untereinheit-Impfstoff
Nerome et al.	1990	Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses
US20080248057A1 (en)	2008-10-09	Multivalent immunogenic composition containing RSV subunit compostion and influenza virus preparation
US4148876A (en)	1979-04-10	Biological preparations
EP0090886A2 (de)	1983-10-12	Stabilisierung von Influenzavirusimpfstoffen
EP2058002A1 (de)	2009-05-13	Rekonstituierte Virushüllen des Respiratory Syncytial Virus und Anwendung als Impfstoff für Respiratory Syncytial Virus
GB1564500A (en)	1980-04-10	Biological preparations
MX2013003451A (es)	2013-09-02	Generacion de particulas de virosoma.
US20020136739A1 (en)	2002-09-26	Subunit respiratory syncytial virus preparation
US20210008195A1 (en)	2021-01-14	Vaccines against hendra and nipah virus infection
Berezin et al.	1985	Isolation and studies of myxovirus glycoproteins
CA2436126A1 (en)	1998-01-22	Subunit respiratory syncytial virus vaccine preparation